Author  
Place of duty  
Title   ECG ¹æ±¤³» ÁÖÀÔ¿ä¹ýÀ»·Î Ä¡·áÇÑ Ç¥À缺 ¹æ±¤¾Ï ȯÀÚÀÇ ¿¹ÈÄ°úÁ¤ ( Prognostic Indexes in Patients Treated with Intravesical Bacillus Calmette - Guerin for Superficial Bladder Cancer )
Publicationinfo   1991 Jan; 023(04): 835-843.
Key_word   Tl bladder tumor, Prognastic factors
Full-Text  
Abstract   We retrospectively analysed the outcome of 166 patients with primary Tl bladder tumor. The mean followup period was 31 months. The overall one, two year recurrence rate an recur- rences per 100 patient-months were 57%, 69% and 6.89 respectively. The progression of the tumor stage developed in 35 patients(21%). The significant prognostic factors with respect to the recurrence were early recurrence pattern(within 6 months), number of the tumors(3 or more) and high tumor grade, but size was less significant. Tumor grade III and early recurrence pattern influenced significantly to the tumor progression. Based on these variables, high risk groups of patients with respect to recurrence and progression can be identified. In high re- currence group, the recurrences per 100 patient-months were 9.70 which were significantly higher than 4.26 of the rest of the patients(p<0.05). In high progression graup, the progression rate was 42% and which increased to 75% if multiplicity and large size were considered as additional factors. Overall 35 patients(21%) progressed to muscle invasive tumors or metastatic disease, l8 of 35 patients(51%) showed progression to muscle invasive tumors(T2 or T3) whereas 17 patients progressed to metastatic disease during a mean period of 24.5 months. Followup plan and definitive treatment decision should be made according to the risk factors of individual patient to reduce or prevent the reeurrence and/or progression. Intensive followup with intravesical therapy or aggressive treatment including early cystectomy were reauired in patients whose tumor showed high risk factors of. recurrence and/ or progression.
Àú ÀÚ   ¹ÚöÈñ(Choal Hee Park),±èõÀÏ(Chun Il Kim),À̼ºÁØ(Sung Choon Lee)